Davidson Kempner Capital Management LP Incyte Corp Transaction History

Davidson Kempner Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $4.76 Million - $5.22 Million	-59,600 Reduced 25.85%	171,000 $14.4 Million
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $8.18 Million - $10.8 Million	107,600 Added 87.48%	230,600 $18.7 Million
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $9.93 Million - $12 Million	123,000 New	123,000 $10.7 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Davidson Kempner Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Davidson Kempner Capital Management LP with notifications on news.